Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RPTR-147 |
Synonyms | |
Therapy Description |
RPTR-147 is a cell therapy that consists of autologous T-lymphocytes primed with PRAME, NYESO-1, SSX2, Survivin, and WT1 tumor associated antigens (TAAs), followed by IL15-Fc nanogel loading, which potentially induces immune response against tumor cells expressing TAAs (Journal for ImmunoTherapy of Cancer 2020;8; Abs nr: 801). |